Prof Anna Vassall

Professor of Health Economics

United Kingdom

Health economist with over thirty years of experience in economic analysis and research in low and middle income countries, with a focus on collaborations that enhance capacity; and inform policy.

Substantial experience in evidence based health sector planning and priority setting, with an emphasis on the generation of health economic evidence for use in policy. Extensive experience supporting national health planning and priority setting, aid effectiveness, and cost-effectiveness analysis in a wide range of countries. Directed and provided economic support to European Community and World Bank funded health sector reform and development projects in Yemen, East Timor, Syria and Sudan: supporting the development of health benefit packages, national strategic plans and medium term expendture frameworks.

Led a wide range of influential economic research on priority setting, costing, poverty and economic impact, financing and economic evaluation. Research topics include HIV prevention for key populations (Avahan programme), the integration and organisation of HIV care and treatment services (Integra project), and new diagnostics for TB (Xpert MTB/RIF) and the prevention of violence against women and girls (What Works). Interested in methods to incorporate health systems and other constraints and a societal/equity focussed perspective into economic evaluation and priority setting. Module organiser for LSHTM's distance learning course in economic evaluation.

Currently Executive Director at the Amsterdam Institute for Global Health and Development and previous Director of LSHTMs Centre for Health Economics in London and co-Director of LSHTM's Global Health Economics Centre. Member of WHO's the Strategic and Technical Advisory Group for TB in SEARO region (STAG- TB SEORO), and for Infections Hazards (STAG-IH). Previously sat on the WHO's Global TB Programme (STAG-TB) and Task Force on Catastrophic Cost Measurement for TB, and on the Lancet Commission for TB; and many Guideline Development Groups. Founding member of the TB-MAC modelling consortium. Lead investigator of the Global Health Costing Consortium; a Bill and Melinda Gates funded project to estimate and analyse HIV, TB and other health service costs globally. Currently supporting several countries develop health benefit packages as part of the Disease Control Priorities (DCP) project and International Decision Support initiative (IDSI). co-Lead investigator of the Exemplars in Primary Health Care project funded by Gates Ventures. Awarded the Joep Lange Chair at the Amsterdam Institute for Global Health, University of Amsterdam in 2018.


Department of Global Health and Development
Faculty of Public Health and Policy


Centre for Epidemic Preparedness and Response
Centre for Evaluation
TB Centre
Global Health Economics Centre


Module Organiser of the Economic Evaluation distance learning module


Evidence based priority setting, economic evaluation, health systems research, capacity strengthening, using of modelling to inform economic analyses

Selected Publications

Count the cost of disability caused by COVID-19.
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
SANDMANN, FG; DAVIES, NG; VASSALL, A; EDMUNDS, WJ; JIT, M; Centre for the Mathematical Modelling of Infectiou,;
medRxiv preprint
Investing in the health of girls and women: a best buy for sustainable development.
Remme, M; VASSALL, A; Fernando, G; Bloom, DE;
Reference case for estimating the costs of global health services and Interventions
VASSALL, A; SWEENEY, S; Kahn, J; GOMEZ GUILLEN, G; Bollinger, L; Marseille, E; Herzel, B; DeCormier Plosky, W; Cunnama, L; Sinanovic, E; Bautista-Arredondo, S; GHCC Technical Advisory Group,; GHCC Stakeholder Group,; Harris, K; Levin, C;
Global Health Cost Consortium
Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study.
Verguet, S; Riumallo-Herl, C; Gomez, GB; Menzies, NA; HOUBEN, RM G J; SUMNER, T; LALLI, M; WHITE, RG; Salomon, JA; Cohen, T; FOSTER, N; Chatterjee, S; SWEENEY, S; Baena, IG; Lönnroth, K; Weil, DE; VASSALL, A;
The Lancet Global health
When an emerging disease becomes endemic.
Science (New York, NY)
Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation.
VASSALL, A; SIAPKA, M; FOSTER, N; Cunnama, L; Ramma, L; FIELDING, K; McCarthy, K; CHURCHYARD, G; GRANT, A; Sinanovic, E;
The Lancet Global health
Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models.
Menzies, NA; Gomez, GB; BOZZANI, F; Chatterjee, S; FOSTER, N; Baena, IG; LAURENCE, YV; Qiang, S; Siroka, A; SWEENEY, S; Verguet, S; Arinaminpathy, N; Azman, AS; Bendavid, E; Chang, ST; Cohen, T; Denholm, JT; Dowdy, DW; Eckhoff, PA; Goldhaber-Fiebert, JD; Handel, A; Huynh, GH; LALLI, M; Lin, H-H; Mandal, S; ... VASSALL, A.
The Lancet Global health
Incorporating Demand and Supply Constraints into Economic Evaluations in Low-Income and Middle-Income Countries.
Health economics
See more information